- Protagonist Therapeutics Inc PTGX announced topline results from its collaboration with Janssen Biotech Inc, a part of Johnson & Johnson JNJ, in the FRONTIER 1 Phase 2b trial of oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis.
- Data from the 255-patient study showed that JNJ-2113 achieved the study's primary efficacy endpoint, with a statistically significant greater proportion of patients achieving PASI-75 (a 75% improvement in skin lesions as measured by the Psoriasis Area and Severity Index) responses compared to placebo at Week 16 in all five treatment groups.
- A clear dose-response was observed across an eight-fold dose range. Treatment was well tolerated, with no meaningful difference in the frequency of adverse events across treatment groups versus placebo.
- Data will be presented from various pre-clinical and clinical studies on JNJ-2113 at medical conferences beginning in the second quarter of 2023.
- JNJ-2113 (formerly PN-235) was discovered and is being developed under the license and collaboration agreement between Protagonist and Janssen Biotech.
- Protagonist completed a Phase 1 study of JNJ-2113 in healthy volunteers in October 2021.
- Janssen retains exclusive, worldwide rights to develop in Phase 2 and beyond and commercialize compounds derived from the research conducted under the agreement against a broad range of indications.
- Price Action: PTGX shares are up 15.20% at $17.51 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
